Biogen Inc
BIIB
Market Cap$27.69B
Close$
$272.05
34.7% upside
Current Fair Value
34.7% upsideUndervalued by 34.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $27.69 Billion |
|---|---|
| Enterprise Value | $33.58 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $7.97 |
| Beta | 0.0 |
| Outstanding Shares | 145,360,798 |
| Avg 30 Day Volume | 1,131,387 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 23.85 |
|---|---|
| PEG | -43.66 |
| Price to Sales | 3.01 |
| Price to Book Ratio | 2.0 |
| Enterprise Value to Revenue | 3.41 |
| Enterprise Value to EBIT | 18.34 |
| Enterprise Value to Net Income | 28 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.47 |
Revenue Sources
No data
ESG Score
No data
About Biogen Inc
7,300 employees
CEO: Josephine Price At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therape...